Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ACP3 | P15309 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222781 | 0.82 | SIGMAR1 (0.36) | L3MBTL1GAASIGMAR1HCRTR2HCRTR1 | |
| SCHEMBL6988968 | 0.82 | SIGMAR1 (0.36) | L3MBTL1GAASIGMAR1HCRTR2HCRTR1 | |
| SCHEMBL1222778 | 0.82 | SIGMAR1 (0.36) | L3MBTL1GAASIGMAR1HCRTR2HCRTR1 | |
| SCHEMBL6994527 | 0.82 | SIGMAR1 (0.36) | L3MBTL1GAASIGMAR1HCRTR2HCRTR1 | |
| SCHEMBL31335170 | 0.75 | SIGMAR1 (0.41) | SIGMAR1HCRTR2HCRTR1POLB | |
| SCHEMBL21210136 | 0.75 | SIGMAR1 (0.41) | SIGMAR1HCRTR2HCRTR1POLB | |
| SCHEMBL13528037 | 0.75 | SIGMAR1 (0.41) | SIGMAR1HCRTR2HCRTR1POLB | |
| SCHEMBL21210139 | 0.75 | SIGMAR1 (0.41) | SIGMAR1HCRTR2HCRTR1POLB | |
| SCHEMBL13528036 | 0.75 | SIGMAR1 (0.41) | SIGMAR1HCRTR2HCRTR1POLB | |
| SCHEMBL13528035 | 0.75 | SIGMAR1 (0.41) | SIGMAR1HCRTR2HCRTR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010007427-A1 | PYRIMIDYL SULFONAMINDE DERIVATIVE AND ITS USE FOR THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016275-A1 | NOVEL COMPOUND 395 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016275-A1 | NOVEL COMPOUND 395 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016275-A1 | NOVEL COMPOUND 395 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016275-A1 | NOVEL COMPOUND 395 | CCL5, CCL2, CCL11 | L3MBTL1 4176/4885GAA 3860/4885SIGMAR1 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.